Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer - Concepedia

Concepedia

Publication | Open Access

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

DOI Full Paper Access

211

Citations

25

References

2019

Year

Panagiotis A. Konstantinopoulos, Weixiu Luo, Joyce F. Liu, D. Gulhan, Carolyn Krasner, Jeffrey J. Ishizuka, Allison Gockley, Mary K. Buss, Whitfield B. Growdon, H. Warren Crowe,

Journal of Clinical Oncology

Abstract

Avelumab exhibited promising activity in MMRD EC regardless of PD-L1 status. IHC for MMR assessment is a useful tool for patient selection. The activity of avelumab in MMRP/non-<i>POLE-</i>mutated ECs was low.

References

	Year	Citations

Page 1